EyePoint Pharmaceuticals, Inc., a specialty biopharma company developing ophthalmic products, has appointed George O. Elston as chief financial officer and head of corporate development. Mr. Elston has previously been a consultant to the company and will now lead the company’s financial, capital markets, and corporate development initiatives. Mr. Elston brings more than 25 years of diverse financial and senior leadership experience in the biopharmaceutical sector with both global publicly-traded and privately-held organizations.

“EyePoint is delighted to welcome George during this exciting period of momentum for our ongoing commercial launches of DEXYCU® and YUTIQ® in the U.S.,” said Nancy Lurker, president and chief executive officer of EyePoint Pharmaceuticals. “George has a proven track record of executing value-creating financial and partnering transactions in the biopharmaceutical sector. His expertise will be greatly beneficial as we continue to build our commercial footprint, while assessing our organic growth and business development pipeline opportunities to expand our ophthalmology reach.”

“DEXYCU and YUTIQ have the potential to change the treatment paradigm for these ocular diseases that represent significant areas of unmet need,” said Mr. Elston. “I look forward to collaborating with the dedicated EyePoint management team and contributing to the future commercial, clinical and operational growth of the Company.” 

Mr. Elston most recently served as chief financial officer and head of corporate development at Enzyvant Therapeutics, where he helped build the pre-commercial rare disease firm leading to its recent acquisition. He previously was president and chief executive officer at 2X Oncology, Inc., where he advanced the company from a spin-out into a multi-program, clinical-stage organization. He has also held senior executive roles at Juniper Pharmaceuticals, Inc. KBI Biopharma and Optherion, Inc. Mr. Elston began his career in public accounting at PriceWaterhouseCoopers.